2023 Alliance for Nanotechnology in Cancer Principal Investigators’ Meeting
October 17 – October 18, 2023
NCI Shady Grove facility Rockville, MD
The 2023 NCI Alliance for Nanotechnology in Cancer Annual Principal Investigator Meeting was held in person at NCI Shady Grove facility on October 17–18, 2023. The meeting gathered the Alliance investigators and collaborators to present their recent research results as well as to discuss emerging opportunities in cancer nanotechnology. The scientific sessions included:
- Nanotechnology-driven immunotherapy, gene therapies, and combination therapies; and
- Cancer interventions enabled by nanomaterials and devices.
The meeting also featured panel discussions on topics “mRNA vaccines for cancer – lessons learned from COVID19” and “NCI resources – support and aid for current and future grantees”.
| Time | Session |
|---|---|
|
9:00 – 9:20 a.m. |
Welcome and Introduction
|
|
9:20 – 10:00 a.m. |
Plenary presentation Engineering the stimulation of natural and synthetic T cells for cancer immunotherapy Darrell Irvine, Ph.D., MASSACHUSETTS INSTITUTE OF TECHNOLOGY |
|
Session I |
NANOTECHNOLOGY-DRIVEN IMMUNOTHERAPY MODERATOR: Piotr Grodzinski, Ph.D., Branch Chief, NSDB, CIP, DCTD, NCI |
|
10:00 – 10:20 a.m. |
Nano-optogenetic control of CAR-T cells for precision immunotherapy with enhanced safety Yubin Zhou, Ph.D., TEXAS A&M UNIVERSITY HEALTH CENTER |
|
10:20 – 10:40 a.m. |
Use of a nano-enabled platform for pancreatic cancer immunotherapy Andre Nel, M.D., Ph.D., UNIVERSITY OF CALIFORNIA LOS ANGELES |
|
10:40 – 11:00 a.m. |
Plant virus nanoparticles for immunotherapy and relapse prevention of ovarian cancer Nicole Steinmetz, Ph.D., UNIVERSITY OF CALIFORNIA, SAN DIEGO |
|
11:00 – 11:20 a.m. |
Break |
|
11:20 – 11:40 a.m. |
Systemic delivery of siRNA by nanosac for checkpoint blockade immunotherapy of head and neck squamous cell cancer Yoon Yeo, Ph.D., PURDUE UNIVERSITY |
|
11:40 a.m – 12:00 p.m. |
Intrapleural immunotherapeutic nanoparticles for MPE treatment Dawen Zhao, M.D., Ph.D., WAKE FOREST UNIVERSITY HEALTH SCIENCES |
|
12:00 – 12:20 p.m. |
Dual action immunostimulatory nanoparticles for treatment of aggressive cancers Efstathios Karathanasis, Ph.D., CASE WESTERN RESERVE UNIVERSITY |
|
12:20 – 1:40 p.m. |
Lunch Break |
|
Session II |
PANEL DISCUSSION: mRNA VACCINES FOR CANCER – LESSONS LEARNED FROM COVID19 MODERATOR: Andre Nel, M.D., Ph.D., UNIVERSITY OF CALIFORNIA LOS ANGELES |
|
1:40 – 3:00 p.m. |
|
|
Session III |
GENE THERAPIES MODERATOR: Leela Rani Avula, Ph.D., Program Director, NSDB, CIP, DCTD, NCI |
|
3:00 – 3:20 p.m. |
Next-gen targeted nanoparticles for inhibiting Gli2 in bone metastatic tumors Julie Rhoades, Ph.D., VANDERBILT UNIVERSITY MEDICAL CENTER |
|
3:20 – 3:40 p.m. |
Developing macrophage reprogramming mRNA nanocarriers for initial clinical testing Matthias Stephan M.D., Ph.D., FRED HUTCHINSON CANCER CENTER |
|
3:40 – 4:00 p.m. |
Targeted RNA delivery using ribonucleoprotein Xiaohu Gao, Ph.D., UNIVERSITY OF WASHINGTON |
|
4:00 – 6:00 p.m. |
POSTER SESSION |
|
Time |
Session |
|---|---|
|
8:30 – 8:40 a.m. |
Day 1 recap Carolina Salvador Morales, Ph.D., Program Director, NSDB, CIP, DCTD, NCI |
|
Session IV |
CANCER INTERVENTIONS ENABLED BY NANOMATERIALS AND DEVICES MODERATOR: Yicong Wu, Ph.D., Program Director, NSDB, CIP, DCTD, NCI |
|
8:40 – 9:00 a.m. |
Magnetofluorescent nanoprobe for the image-guided delivery to glioblastoma John Yu, M.D., CEDARS-SINAI MEDICAL CENTER |
|
9:00 – 9:20 a.m. |
Customized nanofibers with preferential lung-targeting properties for treating metastatic pulmonary tumors Vanessa Bellat, Ph.D., WEILL MEDICAL COLL OF CORNELL UNIVERSITY |
|
9:20 – 9:40 a.m. |
Click Chemistry-Mediated Extracellular Vesicles Enrichment for Characterization of Tumor-Derived Extracellular Vesicles Hsian-Rong Tseng, Ph.D., UNIVERSITY OF CALIFORNIA LOS ANGELES |
|
9:40 – 10:00 a.m. |
Tumor-targeting transformable nanotherapeutic platform against cancer Kit Lam, M.D., Ph.D., UNIVERSITY OF CALIFORNIA AT DAVIS |
|
10:00 – 10:10 a.m. |
Presentation of Poster Awards Siyao Liu, Lian He, Kai Huang, Gang Han, Yubin Zhou, Institute of Biosciences and Technology, Texas A&M University Nano-optogenetics for precision immunotherapy Anthony O. Omole, Jessica F. A. de Oleveira, Lucas Sutorus, Nicole F. Steinmetz, Institute of Engineering in Medicine, University of California, San Diego Ovarian cancer therapy using plant viral nanoparticles Alina Ringaci, Ting-Yu Shih, Christopher Gromisch, Aladin Hamoud, Samantha M. Berry, Yolonda L. Colson, Mark W. Grinstaff, College of Engineering, Boston University Self-assembled Nano-zip Antibody Drug Conjugate for the treatment of HER2-positive breast cancer James G. Shamul, Xiaoming He, Department of Bioengineering, University of Maryland, College Park A meta-analysis of engineered blood brain barriers in vitro |
|
10:10 – 10:40 a.m. |
Break |
|
Session V |
NCI RESOURCES – SUPPORT AND AID FOR CURRENT AND FUTURE GRANTEES MODERATOR: Piotr Grodzinski, Ph.D., Branch Chief, NSDB, CIP, DCTD, NCI |
|
10:40 – 11:00 a.m. |
Grant policies, beyond R01s Leela Rani Avula, Ph.D., NSDB, CIP, DCTD, NCI |
|
11:00 – 11:20 a.m. |
NCL overview Marina Dobrovolskaia, Ph.D., NCL, FNLCR |
|
11:20 – 11:40 a.m. |
caNanoLab database overview Weina Ke, Ph.D., FNLCR |
|
Session VI |
COMBINATION THERAPIES MODERATOR: Carolina Salvador Morales, Ph.D., Program Director, NSDB, CIP, DCTD, NC |
|
11:40 am – 12:00 p.m. |
Pre-IND development of polymeric micelles with dual drug payloads for HCC therapy Chun Li, Ph.D., UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER |
|
12:00 – 12:20 p.m. |
Inhibition of iRhom by CD44-targeting Nanocarrier for Improved Cancer Immunochemotherapy Song Li, M.D., Ph.D., UNIVERSITY OF PITTSBURGH AT PITTSBURGH |
|
12:20 – 12:40 p.m. |
Nano-beter Paclitaxel by Polymeric Micelles, Prodrug Nanotechnology, and mTOR Inhibition Glen Kwon, Ph.D., UNIVERSITY OF WISCONSIN-MADISON |
|
12:40 – 1:00 p.m. |
Nanoscale Metal-Organic Framework for the Treatment of Head and Neck Cancer Wenbin Lin, Ph.D., UNIVERSITY OF CHICAGO |
|
1:00 – 1:20 p.m. |
Closing remarks Piotr Grodzinski, Ph.D., Branch Chief, NSDB, CIP, DCTD, NCI |